Kevin Holden, Ph.D.

Kevin Holden, Ph.D. is CEO and co-founder of NV Therapeutics in Berkeley, California.

Kevin has over 20 years of experience in biotechnology startups, with expertise spanning CRISPR genome engineering, synthetic biology, and the development and commercialization of novel biotechnology platforms. His career has focused on translating emerging scientific technologies into commercially viable products, scaling early-stage biotechnology companies, building strategic partnerships, and advancing innovative approaches to genetic engineering.

Prior to co-founding NV Therapeutics, Kevin spent eight years at Synthego, where he played a key role in the company’s growth and commercialization of its CRISPR genome engineering technologies. As Vice President of Science, he led scientific strategy, research teams, and strategic partnerships, helping drive the adoption of genome engineering technologies across research and therapeutic development. Kevin completed his training in Microbiology and Biotechnology at the University of California, Davis.

At NV Therapeutics, Kevin leads the company’s corporate and scientific strategy, business development, and organizational growth, drawing on his experience in genome engineering and biotechnology commercialization to advance its non-viral gene writing platform and the development of next-generation genetic medicines.